SHORT REPORT

Interferon beta in multiple sclerosis: experience in a British specialist multiple sclerosis centre

B D Dubois, E Keenan, B E Porter, R Kapoor, P Rudge, A J Thompson, D H Miller, G Giovannoni

Background: The efficacy of interferon beta (IFN beta) is well established in relapsing-remitting multiple sclerosis (MS). However, the use of this drug in clinical practice is complex, especially because it is only partially effective, its long term efficacy and side effects are unknown, its efficacy may be abrogated by the development of neutralising antibodies, compliance is variable, and its cost effectiveness is controversial.

Objectives and Methods: Analysis of a prospectively followed up series of 101 MS patients treated with IFN beta was undertaken to: (1) monitor the outcome of IFN beta treatment in clinical practice; (2) compare the immunogenicity of the three commercial IFN beta preparations available; (3) assess the proportion of patients fulfilling the current guidelines of the Association of British Neurologists for stopping IFN beta therapy.

Results: During a median treatment period of 26 months (range 2–85), the relapse rate decreased by 41%. Although the reduction in the relapse rate was similar for all three commercial products, none of the Avonex treated patients were relapse free, compared with 19% of the Betaferon treated and 27% of the Rebif treated patients (p=0.02). Neutralising antibodies were not detected in Avonex treated patients (0 of 18), compared with 12 of 32 (38%) Betaferon treated and 10 of 23 (44%) Rebif treated patients (p=0.02). Forty of 101 (40%) patients satisfied the current (2001) Association of British Neurologists criteria for stopping IFN beta treatment at some stage during their treatment.

Conclusion: IFN beta is effective in reducing the relapse rate in patients with relapsing-remitting MS in routine clinical practice. However, after a median treatment duration of 26 months, 40% of initially relapsing-remitting MS patients seem to have ongoing disease activity, presenting as disabling relapses or insidious progression.

The aims of the audit were therefore (1) to evaluate the efficacy of IFN beta treatment in clinical practice; (2) to establish the immunogenicity of the different products and correlate the occurrence of neutralising antibodies (NABs) with clinical parameters; (3) to assess “failure of treatment” as defined by the recently published guidelines from the Association of British Neurologists (ABN).

METHODS

Patients

An analysis was performed on all patients with relapsing-remitting MS who started IFN beta therapy before 1 January 2000 at the NHNN in London. Only patients who experienced at least two clinically significant relapses during the previous two years and had an Expanded Disability Status Scale (EDSS) score of less than 5.5 were given IFN beta. A minimum follow up period of at least 12 months at the NHNN was required to be included in the audit.

Demographic and efficacy parameters

The following parameters were assessed during the analysis: age at onset of disease, duration of disease, duration of treatment, and the IFN beta product. Disease course, relapse rate, time of relapse, corticosteroid use, and mobility were evaluated before treatment and at the end of the assessment period. Patients were classified as having secondary progressive disease only if there was a clear progression in at least the preceding six months without the interference of episodes. The annualised relapse rate and use of corticosteroids in the two years before treatment were compared with the respective rates on treatment. Relapses were defined as disabling if they required corticosteroid administration. Disability was not formally assessed with the EDSS but was prospectively scored using the following simple mobility scale: 0=asymptomatic; 1=able to walk unaided for more than 500 m; 2=able to walk unaided for less than 500 m; 3=walking with unilateral support; 4=walking with bilateral support; 5=needs wheelchair outdoors; 6=wheelchair bound.

The proportion of patients fulfilling the current guidelines of the ABN for stopping IFN beta therapy was also assessed. The ABN considers the following features as likely to indicate a lack of treatment efficacy:

(1) two disabling relapses, as defined by the examining neurologist, within a 12 months period
(2) development of secondary progressive MS
(3) loss of ability to walk, with or without assistance, persistent for at least six months

Abbreviations: IFN beta, interferon beta; MS, multiple sclerosis; NAB, neutralising antibody; EDSS, Expanded Disability Status Scale; ABN, Association of British Neurologists
neutralising anti-IFN beta antibodies
Neutralising anti-IFN beta-1a and beta-1b antibodies were tested for in serum of patients in whom blood samples were taken at baseline and one year after treatment onset using a standard cytopathic effect assay in an independent laboratory. Samples were coded and assayed blind.

Statistical analysis
Means and standard deviations of the mean were calculated for relapse rate, corticosteroid use, and mobility before and on treatment as well as on the absolute and relative differences of these parameters before treatment and at the end of the assessment period. The means of the duration of disease, the duration of treatment, and the age at onset of disease were also analysed. Statistical analysis on these mean values was performed using a paired sample or an independent samples t test. Fisher’s exact test was used to compare numbers of relapse free patients in various subgroups. Differences between products were assessed by one way analysis of variance. Influence of NABs on number of relapse free patients or patients becoming secondary progressive was assessed using the χ² statistical method. Results were considered statistically significant if p<0.05.

RESULTS
The data concerning demographics, treatment efficacy, NABs, and stopping criteria are shown in table 1.

Patients
One hundred and one patients (67 women, 34 men) were started on IFN beta before 1 January 2000 and were followed up at the NHNN for at least 12 months. The median duration of treatment was 26 months (range 12–85). Five patients stopped treatment: two because of pregnancy and three (one taking Avonex, two taking Betaferon) because of lack of efficacy and persistent side effects. Five patients changed product during the assessment period. They were included in the general analysis, but not in the analyses that involved product comparisons.

Treatment efficacy
Relapse rate and corticosteroid use were significantly reduced after treatment with IFN beta. However, mobility worsened on the mobility scale (p<0.001).

Twenty three patients (22.8%, six taking Avonex, eight taking Betaferon, six taking Rebif, and three who changed products) developed secondary progressive disease by the end of the assessment period. No significant differences were found between the products in regard to their effect on relapse rate, corticosteroid use, and mobility. However, the number of relapse free patients differed significantly between the various products. None of the Avonex treated patients (0 of 22) was relapse free whereas seven of 37 (19%) Betaferon and 10 of 37 (27%) Rebif treated patients did not experience relapses during the treatment period (p=0.02) (fig 1).

Neutralising anti-IFN beta antibodies
General analysis
NAB test results after one year of IFN beta therapy were available in 73 (48 female, 25 male) of the 101 relapsing-remitting patients. Anti-IFN beta antibodies were found in 22 (30%) of these 73 patients. In three (4%) patients (one taking Betaferon, two taking Rebif) the antibodies were not cross reactive between the IFN beta-1b and beta-1a preparations. The means of the various demographic and clinical data were compared in antibody negative versus antibody positive patients. No significant differences were found for relapse rate, corticosteroid use, and mobility at baseline and at the end of

Table 1  Demographic and efficacy data of relapsing-remitting MS patients, treated with interferon beta for at least 12 months.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>All products</th>
<th>Avonex</th>
<th>Betaferon</th>
<th>Rebif</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>n=101</td>
<td>n=24</td>
<td>n=37</td>
<td>n=37</td>
</tr>
<tr>
<td>Demographics</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>age at onset of disease (y)</td>
<td>27.6 (7.0)</td>
<td>27.4 (6.9)*</td>
<td>26.6 (6.3)*</td>
<td>29.2 (8.0)*</td>
</tr>
<tr>
<td>duration of disease (y)</td>
<td>9.5 (6.3)</td>
<td>9.0 (4.8)*</td>
<td>9.5 (5.7)*</td>
<td>10.0 (7.8)*</td>
</tr>
<tr>
<td>duration of treatment (m)</td>
<td>29.4 (13.3)</td>
<td>29.8 (8.2)†</td>
<td>38.2 (12.6)†</td>
<td>19.2 (3.6)†</td>
</tr>
<tr>
<td>Efficacy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>relapse rate at baseline</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>relapse rate on treatment</td>
<td>1.9 (0.9)</td>
<td>2.2 (1.3)*</td>
<td>1.9 (0.7)*</td>
<td>1.9 (0.7)*</td>
</tr>
<tr>
<td>relapse free</td>
<td>16/96 (16.7%)</td>
<td>0/22†</td>
<td>7/37 (19%)‡</td>
<td>10/37 (27%)‡</td>
</tr>
<tr>
<td>corticosteroid use at baseline</td>
<td>0.9 (0.7)†</td>
<td>1.1 (0.8)*</td>
<td>0.9 (0.6)*</td>
<td>0.8 (0.7)*</td>
</tr>
<tr>
<td>corticosteroid use on treatment</td>
<td>0.6 (1.0)‡</td>
<td>0.7 (1.2)*</td>
<td>0.6 (1.2)*</td>
<td>0.6 (0.8)*</td>
</tr>
<tr>
<td>mobility at baseline</td>
<td>1.4 (1.3)†</td>
<td>1.4 (0.9)*</td>
<td>1.4 (0.9)*</td>
<td>1.4 (0.8)*</td>
</tr>
<tr>
<td>mobility on treatment</td>
<td>2.1 (1.6)†</td>
<td>2.2 (1.7)*</td>
<td>2.1 (1.7)*</td>
<td>2.0 (1.6)*</td>
</tr>
<tr>
<td>SP on treatment</td>
<td>23/101 (22.8%)</td>
<td>7/24 (29.2%)</td>
<td>9/37 (24.3%)</td>
<td>6/37 (16.2%)</td>
</tr>
<tr>
<td>early discontinuation</td>
<td>5</td>
<td>2</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Neutralising antibodies</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>22/73 (30.1%)</td>
<td>0/18</td>
<td>12/32 (38%)</td>
<td>10/23 (44%)</td>
</tr>
<tr>
<td>ABN stopping criteria</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>relapses or secondary progression</td>
<td>40/101 (39.6%)</td>
<td>10/24 (41.7%)</td>
<td>16/37 (43.2%)</td>
<td>13/37 (35.1%)</td>
</tr>
<tr>
<td>relapses</td>
<td>17/101 (16.8%)</td>
<td>3/24 (12.5%)</td>
<td>7/37 (18.9%)</td>
<td>7/37 (18.9%)</td>
</tr>
<tr>
<td>secondary progression</td>
<td>15/101 (14.9%)</td>
<td>4/24 (16.7%)</td>
<td>6/37 (16.2%)</td>
<td>4/37 (10.8%)</td>
</tr>
<tr>
<td>relapses and secondary progression</td>
<td>8/101 (7.9%)</td>
<td>3/24 (12.5%)</td>
<td>3/37 (8.1%)</td>
<td>2/37 (5.4%)</td>
</tr>
<tr>
<td>inability to walk</td>
<td>2/101 (2%)</td>
<td>1/24 (4.2%)</td>
<td>1/37 (2.7%)</td>
<td>0/24 (0%)</td>
</tr>
</tbody>
</table>

*p value not significant; †p<0.001; ‡p=0.02.
the assessment period, relative and absolute changes in relapse rate, corticosteroid use, and mobility. The presence of antibodies did not change the number of relapse free patients or the number of patients becoming secondary progressive.

Comparison of agents

None of the Avonex treated patients developed antibodies (0 of 18), whereas 12 (38%) of the Betaferon treated and 10 (44%) of the Rebif treated patients did. When antibody positive (n=12) and antibody negative (n=20) patients taking Betaferon were compared, a trend (p=0.08) towards a higher reduction in relative relapse rate was seen in antibody negative patients (antibody negative 56% v antibody positive 20%). Antibody negative patients were not more often relapse free. Similar analyses were performed in antibody positive (n=10) and antibody negative (n=13) patients who were treated with Rebif and no significant differences were found regarding the efficacy parameters.

Treatment failure according to the ABN stopping criteria

Of the 101 relapsing-remitting MS patients, 40 (40%) fulfilled the current ABN criteria for stopping therapy during the audit. Eight (8%) patients met both the first two stopping criteria (two disabling relapses within a 12 month period and the subsequent development of secondary progression), 15 (15%) became secondary progressive (two of these patients also fulfilled the third stopping criterion), and 17 (17%) had at least two disabling (for example, requiring corticosteroids) relapses within a 12 month period. In 24 of 25 of these patients with two disabling relapses within a 12 month period, these occurred within 18 months of starting treatment. The change in relapse frequencies during these first 18 months of the treatment was a relatively good predictor for the subsequent follow up period. However, despite fulfilling the ABN stopping criteria, six (24%) of the 25 patients with at least two disabling relapses had a reduced relapse rate on treatment compared with the two years before starting treatment. On the other hand, five of 101 patients who did not fulfill the ABN stopping criteria had an increased relapse frequency compared with the two years before starting treatment, although these relapses were non-disabling.

DISCUSSION

Although the indication for using IFN beta in relapsing-remitting MS is based on large placebo controlled clinical trials, treatment of patients with this disease modifying agent should be reviewed in clinical practice. Reasons for this include the partial effect of the drug, the difficulty in distinguishing “responders” from “non-responders”, the unknown long term efficacy and side effects and the high cost of the therapy. This audit reports the NNHNN’S experience from the first four years of IFN beta therapy in MS. It must be emphasised that this was an unblinded observational audit with a comparatively small number of patients, particularly for the subgroup analyses.

The results on efficacy of IFN beta treatment in our patients are largely consistent with the published trial data.

Within the limitations that the number of patients was small and treatment not being randomly allocated, all three agents seemed to reduce relapse frequency to a similar extent. A proportion of patients taking the more frequent doses of the subcutaneous preparations became relapse free (fig 1). This is in accordance with recent comparative studies. The preparations differed in their immunogenic profile. NABs were found in none of the Avonex treated patients, whereas 38% of the Betaferon treated, and 44% of Rebif treated patients were positive. This difference in the immunogenicity is in keeping with previously reported data. It has recently been demonstrated that NABs reduce IFN beta’s therapeutic effect but this only became apparent after four years of observation. This may explain why no clinical effects of NABs were noted in our audit. Interestingly, a trend was seen in patients on Betaferon who had received IFN beta the longest.

Finally, although IFN beta therapy was only stopped because of apparent lack of efficacy in 3% of patients, 40% of our patients would have fulfilled the current ABN criteria for stopping therapy. More than half of those (62.5%) had at least two disabling relapses in 12 months and 57.5% developed secondary progressive disease, with or without superimposed relapses. The time point at which the disabling relapse criterion was fulfilled demonstrates that the treatment response with regard to disabling relapses might be evaluated after as little as 18 months of IFN beta therapy. Analysis of the disease course of the 25 patients who fulfil the ABN criteria on relapses for stopping therapy highlight important features that should be taken into account. Of these 25 patients, 10 (40%) experienced a lower or equal number of relapses compared with baseline. On the other hand, five of 101 relapsing-remitting MS patients who had a higher relapse rate on treatment than at baseline, did not fulfill the ABN stopping criteria. These data question the current wisdom of defining a stopping criterion based solely on the number of disabling relapses. This will be difficult to implement on an individual patient basis particularly as IFN beta therapy is widely acknowledged to being only a partially effective therapy. It would be more appropriate to include both the baseline relapse rate and the severity of relapses in formulating a relapse based stopping criterion. In contrast, conversion to secondary progressive MS, which is more difficult to evaluate than relapses, may be a more practical stopping criterion to implement, particularly as IFN beta treatment does not show a robust effect in patients with secondary progressive MS. The future evaluation of the appropriateness of stopping criteria may be assisted by using objective predefined markers of disease activity or progression, or both. Examples of these could include magnetic resonance imaging parameters or NABs.

ACKNOWLEDGEMENTS

The authors thank H Watt for statistical advice. B Dubois was a research assistant of the Fund for Scientific Research (FWO-Vlaanderen) and was supported by the Scientific Research for Multiple Sclerosis (Wetenschappelijk Onderzoek Multiple Sclerose, WOMS, Belgium) and by a Glaxo-Smith-Kline Grant in Neurology.

Authors’ affiliations

B D Dubois, E Keenan, B E Porter, R Kapoor, P Rudge, A J Thompson, D H Miller, G Giovannoni, Institute of Neurology and National Hospital for Neurology and Neurosurgery, London, UK

PRISMS Study Group

Correspondence to: Dr G Giovannoni, Department of Neuroinflammation, Institute of Neurology, Queen Square, London WC1N 3BG, UK; G.Giovannoni@ion.ucl.ac.uk

Received 6 February 2002

Accepted in final revised form 28 January 2003

REFERENCES

Interferon beta in clinical practice


HISTORICAL NOTE

Sir James Crichton-Browne (1840–1938)

James Crichton-Browne was born in Edinburgh, the son of Dr WAF Browne, first superintendent of Crichton Royal, Dumfries. James was educated in Dumfries and began his medical studies at Edinburgh University in 1857, a pupil of Joseph Lister (1827–1912) and James Syme (1799–1879).

His interests in psychiatry were soon evident. As a medical student he read a paper to the Royal Medical Society, The psychical diseases of early life. Crichton-Browne graduated in 1861, and obtained the MD in 1862. He worked in asylums in Derby, Devon, and Newcastle. In 1866, at the early age of 26, he was appointed as Superintendent Medical Director of the West Riding Lunatic Asylum at Wakefield, and in nine years established the hospital as a leading centre of research and treatment. Though lacking Ferrier’s scientific ability, he was a skilled administrator and a flamboyant highly persuasive speaker. He inaugurated the Annual medical reports of the West Riding Asylum in 1871, which were published annually for six years, and 62 of these 79 articles came from Wakefield Asylum. And he appointed a pathologist, the first to occupy a research laboratory within an asylum. He attracted many talented young men to cooperate in his research. They included David Ferrier and Hughlings Jackson, who worked on cerebral localisation, and on epilepsy. They painstakingly studied clinical phenomena and the neuropathology of their patients. For instance, in general paralysis of the insane, over 1500 autopsies were performed. In search of therapies, Crichton-Browne also experimented with the effects of electrical stimulation of the cranium (analogous to ECT) and investigated the effects of ergot, nitrous oxide, and opium. One can understand the high reputation of their medical reports of the West Riding Asylum. In 1878, Crichton-Browne with Ferrier, Jackson, and Boyd, 1924.

In 1881, Crichton-Browne succeeded Lytton, writer (1803–1873), who coined the memorable adage, ‘A good heart is better than all the heads in the world’.

A portrait of Crichton-Browne by Hannah Gluckstein, 1928, is catalogued at the National Portrait Gallery. And you may not wish to learn that he was portrayed on a cigarette card in a series on Famous Scots published by Mitchell, Ardath in 1935. His recipe for longevity was—‘work and plenty of it’.

References


4 Crichton Browne J. Stray leaves from a physician’s portfolio. London: Hodder and Stoughton, 1927.

5 Crichton-Browne J. The nemesis of Froude: a rejoinder to J A Froude’s “My Relations with Carlyle”. London and New York: John Lane, 1903.
Interferon beta in multiple sclerosis: experience in a British specialist multiple sclerosis centre

B D Dubois, E Keenan, B E Porter, R Kapoor, P Rudge, A J Thompson, D H Miller and G Giovannoni

J Neurol Neurosurg Psychiatry 2003 74: 946-949
doi: 10.1136/jnnp.74.7.946

Updated information and services can be found at:
http://jnnp.bmj.com/content/74/7/946

These include:

References
This article cites 15 articles, 6 of which you can access for free at:
http://jnnp.bmj.com/content/74/7/946#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Immunology (including allergy) (1943)
Multiple sclerosis (934)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/